113 results on '"Lecka-Czernik B"'
Search Results
2. Neurotrophic factor-α1 prevents stress-induced depression through enhancement of neurogenesis and is activated by rosiglitazone
- Author
-
Cheng, Y, Rodriguiz, R M, Murthy, S R K, Senatorov, V, Thouennon, E, Cawley, N X, Aryal, D K, Ahn, S, Lecka-Czernik, B, Wetsel, W C, and Loh, Y P
- Published
- 2015
- Full Text
- View/download PDF
3. Bone marrow fat has brown adipose tissue characteristics, which are attenuated with aging and diabetes
- Author
-
Krings, A., Rahman, S., Huang, S., Lu, Y., Czernik, P.J., and Lecka-Czernik, B.
- Published
- 2012
- Full Text
- View/download PDF
4. Decreased osteoclastogenesis and high bone mass in mice with impaired insulin clearance due to liver-specific inactivation to CEACAM1
- Author
-
Huang, S., Kaw, M., Harris, M.T., Ebraheim, N., McInerney, M.F., Najjar, S.M., and Lecka-Czernik, B.
- Published
- 2010
- Full Text
- View/download PDF
5. Reconstitution of the host holobiont in germ-free rats acutely increases bone growth and affects marrow cellular content
- Author
-
Czernik, PJ, primary, Golonka, RM, additional, Chakraborty, S, additional, Yeoh, BS, additional, Abokor, A, additional, Saha, P, additional, Yeo, JY, additional, Mell, B, additional, Cheng, X, additional, Baroi, S, additional, Joe, B, additional, Vijay-Kumar, M, additional, and Lecka-Czernik, B, additional
- Published
- 2020
- Full Text
- View/download PDF
6. Activation of Peroxisome Proliferator-Activated Receptor γ (PPARγ) by Rosiglitazone Suppresses Components of the Insulin-Like Growth Factor Regulatory System in Vitro and in Vivo
- Author
-
Lecka-Czernik, B, Ackert-Bicknell, C, Adamo, M L., Marmolejos, V, Churchill, G A., Shockley, K R., Reid, I R., Grey, A, and Rosen, C J.
- Published
- 2007
7. Bone Is a Target for the Antidiabetic Compound Rosiglitazone
- Author
-
Rzonca, S O., Suva, L J., Gaddy, D, Montague, D C., and Lecka-Czernik, B
- Published
- 2004
8. PPARG Post-translational Modifications Regulate Bone Formation and Bone Resorption
- Author
-
Stechschulte, L.A., primary, Czernik, P.J., additional, Rotter, Z.C., additional, Tausif, F.N., additional, Corzo, C.A., additional, Marciano, D.P., additional, Asteian, A., additional, Zheng, J., additional, Bruning, J.B., additional, Kamenecka, T.M., additional, Rosen, C.J., additional, Griffin, P.R., additional, and Lecka-Czernik, B., additional
- Published
- 2016
- Full Text
- View/download PDF
9. High bone mass in adult mice with diet-induced obesity results from a combination of initial increase in bone mass followed by attenuation in bone formation; implications for high bone mass and decreased bone quality in obesity
- Author
-
Lecka-Czernik, B., primary, Stechschulte, L.A., additional, Czernik, P.J., additional, and Dowling, A.R., additional
- Published
- 2015
- Full Text
- View/download PDF
10. A circadian-regulated gene, Nocturnin, promotes adipogenesis by stimulating PPAR- nuclear translocation
- Author
-
Garg, N., Green, C. B., Rosen, C. J., Kawai, M., Ackert-Bicknell, C., Adamo, M. L., Horowitz, M. C., Kojima, S., Clemmons, D. R., Lecka-Czernik, B., Douris, N., and Gilbert, M. R.
- Abstract
Nocturnin (NOC) is a circadian-regulated protein related to the yeast family of transcription factors involved in the cellular response to nutrient status. In mammals, NOC functions as a deadenylase but lacks a transcriptional activation domain. It is highly expressed in bone-marrow stromal cells (BMSCs), hepatocytes, and adipocytes. In BMSCs exposed to the PPAR-γ (peroxisome proliferator-activated receptor-γ) agonist rosiglitazone, Noc expression was enhanced 30-fold. Previously, we reported that Noc−/− mice had low body temperature, were protected from diet-induced obesity, and most importantly exhibited absence of Pparg circadian rhythmicity on a high-fat diet. Consistent with its role in influencing BMSCs allocation, Noc−/− mice have reduced bone marrow adiposity and high bone mass. In that same vein, NOC overexpression enhances adipogenesis in 3T3-L1 cells but negatively regulates osteogenesis in MC3T3-E1 cells. NOC and a mutated form, which lacks deadenylase activity, bind to PPAR-γ and markedly enhance PPAR-γ transcriptional activity. Both WT and mutant NOC facilitate nuclear translocation of PPAR-γ. Importantly, NOC-mediated nuclear translocation of PPAR-γ is blocked by a short peptide fragment of NOC that inhibits its physical interaction with PPAR-γ. The inhibitory effect of this NOC-peptide was partially reversed by rosiglitazone, suggesting that effect of NOC on PPAR-γ nuclear translocation may be independent of ligand-mediated PPAR-γ activation. In sum, Noc plays a unique role in the regulation of mesenchymal stem-cell lineage allocation by modulating PPAR-γ activity through nuclear translocation. These data illustrate a unique mechanism whereby a nutrient-responsive gene influences BMSCs differentiation, adipogenesis, and ultimately body composition.
- Published
- 2010
- Full Text
- View/download PDF
11. Neurotrophic factor-α1 prevents stress-induced depression through enhancement of neurogenesis and is activated by rosiglitazone
- Author
-
Cheng, Y, primary, Rodriguiz, R M, additional, Murthy, S R K, additional, Senatorov, V, additional, Thouennon, E, additional, Cawley, N X, additional, Aryal, D K, additional, Ahn, S, additional, Lecka-Czernik, B, additional, Wetsel, W C, additional, and Loh, Y P, additional
- Published
- 2014
- Full Text
- View/download PDF
12. A Chromosomal Inversion within a Quantitative Trait Locus Has a Major Effect on Adipogenesis and Osteoblastogenesis
- Author
-
ACKERT-BICKNELL, C. L., primary, SALISBURY, J. L., additional, HOROWITZ, M., additional, DEMAMBRO, V. E., additional, HORTON, L. G., additional, SHULTZ, K. L., additional, LECKA-CZERNIK, B., additional, and ROSEN, C. J., additional
- Published
- 2007
- Full Text
- View/download PDF
13. PPARγ2 Regulates a Molecular Signature of Marrow Mesenchymal Stem Cells
- Author
-
Shockley, K. R., primary, Rosen, C. J., additional, Churchill, G. A., additional, and Lecka-Czernik, B., additional
- Published
- 2007
- Full Text
- View/download PDF
14. Cellular and Molecular Biomarkers Indicate Precocious in vitro Senescence in Fibroblasts From SAMP6 Mice: Evidence Supporting a Murine Model of Premature Senescence and Osteopenia
- Author
-
Lecka-Czernik, B., primary, Moerman, E. J., additional, Reis, R. J. S., additional, and Lipschitz, D. A., additional
- Published
- 1997
- Full Text
- View/download PDF
15. INCREASED MARROW ADIPOGENESIS IN THE MURINE MODEL OF DEFECTIVE OSTEOBLASTOGENESIS 109
- Author
-
Kajkenova, O, primary, Lecka-Czernik, B, additional, Gubrij, I, additional, Jilka, R L, additional, and Lipschtz, D A, additional
- Published
- 1997
- Full Text
- View/download PDF
16. An overexpressed gene transcript in senescent and quiescent human fibroblasts encoding a novel protein in the epidermal growth factor-like repeat family stimulates DNA synthesis
- Author
-
Lecka-Czernik, B, primary, Lumpkin, C K, additional, and Goldstein, S, additional
- Published
- 1995
- Full Text
- View/download PDF
17. Identification of gene sequences overexpressed in senescent and Werner syndrome human fibroblasts
- Author
-
Lecka-Czernik, B., Moerman, E. J., Jones, R. A., and Goldstein, S.
- Published
- 1996
- Full Text
- View/download PDF
18. Analysis of replication of DEB-alkylated DNA in yeast: bypass replication in a rad3 mutant of Saccharomyces cerevisiae
- Author
-
Lecka-Czernik, B., primary, Swietlińska, Z., additional, Zaborowska, D., additional, and Żuk, J., additional
- Published
- 1984
- Full Text
- View/download PDF
19. PPARG in osteocytes controls cell bioenergetics and systemic energy metabolism independently of sclerostin levels in circulation.
- Author
-
Baroi S, Czernik PJ, Khan MP, Letson J, Crowe E, Chougule A, Griffin PR, Rosen CJ, and Lecka-Czernik B
- Subjects
- Animals, Mice, Male, Female, Oxidative Stress, Mice, Knockout, Mitochondria metabolism, Mice, Inbred C57BL, Energy Metabolism, Osteocytes metabolism, Adaptor Proteins, Signal Transducing metabolism, Adaptor Proteins, Signal Transducing genetics, PPAR gamma metabolism, PPAR gamma genetics
- Abstract
Objective: The skeleton is one of the largest organs in the body, wherein metabolism is integrated with systemic energy metabolism. However, the bioenergetic programming of osteocytes, the most abundant bone cells coordinating bone metabolism, is not well defined. Here, using a mouse model with partial penetration of an osteocyte-specific PPARG deletion, we demonstrate that PPARG controls osteocyte bioenergetics and their contribution to systemic energy metabolism independently of circulating sclerostin levels, which were previously correlated with metabolic status of extramedullary fat depots., Methods: In vivo and in vitro models of osteocyte-specific PPARG deletion, i.e. Dmp1
Cre Pparγflfl male and female mice (γOTKO ) and MLO-Y4 osteocyte-like cells with either siRNA-silenced or CRISPR/Cas9-edited Pparγ. As applicable, the models were analyzed for levels of energy metabolism, glucose metabolism, and metabolic profile of extramedullary adipose tissue, as well as the osteocyte transcriptome, mitochondrial function, bioenergetics, insulin signaling, and oxidative stress., Results: Circulating sclerostin levels of γOTKO male and female mice were not different from control mice. Male γOTKO mice exhibited a high energy phenotype characterized by increased respiration, heat production, locomotion and food intake. This high energy phenotype in males did not correlate with "beiging" of peripheral adipose depots. However, both sexes showed a trend for reduced fat mass and apparent insulin resistance without changes in glucose tolerance, which correlated with decreased osteocytic responsiveness to insulin measured by AKT activation. The transcriptome of osteocytes isolated from γOTKO males suggested profound changes in cellular metabolism, fuel transport, mitochondria dysfunction, insulin signaling and increased oxidative stress. In MLO-Y4 osteocytes, PPARG deficiency correlated with highly active mitochondria, increased ATP production, and accumulation of reactive oxygen species (ROS)., Conclusions: PPARG in male osteocytes acts as a molecular break on mitochondrial function, and protection against oxidative stress and ROS accumulation. It also regulates osteocyte insulin signaling and fuel usage to produce energy. These data provide insight into the connection between osteocyte bioenergetics and their sex-specific contribution to the balance of systemic energy metabolism. These findings support the concept that the skeleton controls systemic energy expenditure via osteocyte metabolism., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier GmbH.. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
20. Regulatory Effect of Osteocytes on Extramedullary and Bone Marrow Adipose Tissue Development and Function.
- Author
-
Lecka-Czernik B, Khan MP, Letson J, Baroi S, and Chougule A
- Subjects
- Humans, PPAR alpha metabolism, Animals, Osteocytes metabolism, Osteocytes physiology, PPAR gamma metabolism, Bone Marrow metabolism, Adipose Tissue metabolism, Adipocytes metabolism, Energy Metabolism physiology
- Abstract
Purpose of Review: This review summarizes evidence on osteocyte support of extramedullary and bone marrow adipocyte development and discusses the role of endogenous osteocyte activities of nuclear receptors peroxisome proliferator-activated receptor gamma (PPARG) and alpha (PPARA) in this support., Recent Findings: PPARG and PPARA proteins, key regulators of glucose and fatty acid metabolism, are highly expressed in osteocytes. They play significant roles in the regulation of osteocyte secretome and osteocyte bioenergetics; both activities contributing to the levels of systemic energy metabolism in part through an effect on metabolic function of extramedullary and bone marrow adipocytes. The PPARs-controlled osteocyte endocrine/paracrine activities, including sclerostin expression, directly regulate adipocyte function, while the PPARs-controlled osteocyte fuel utilization and oxidative phosphorylation contribute to the skeletal demands for glucose and fatty acids, whose availability is under the control of adipocytes. Bone is an inherent element of systemic energy metabolism with PPAR nuclear receptors regulating osteocyte-adipocyte metabolic axes., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
21. Diabetes increases risk of lumbar spinal fusion complications: association with altered structure of newly formed bone at the fusion site.
- Author
-
Wilson C, Czernik PJ, Elgafy H, Khuder S, Serdahely K, Rowland A, and Lecka-Czernik B
- Abstract
Diabetes predisposes to spine degenerative diseases often requiring surgical intervention. However, the statistics on the prevalence of spinal fusion success and clinical indications leading to the revision surgery in diabetes are conflicting. The purpose of the presented retrospective observational study was to determine the link between diabetes and lumbar spinal fusion complications using a database of patients ( n = 552, 45% male, age 54 ± 13.7 years) residing in the same community and receiving care at the same health care facility. Outcome measures included clinical indications and calculated risk ratio (RR) for revision surgery in diabetes. Paravertebral tissue recovered from a non-union site of diabetic and nondiabetic patients was analyzed for microstructure of newly formed bone. Diabetes increased the RR for revision surgery due to non-union complications (2.80; 95% CI, 1.12-7.02) and degenerative processes in adjacent spine segments (2.26; 95% CI, 1.45-3.53). In diabetes, a risk of revision surgery exceeded the RR for primary spinal fusion surgery by 44% (2.36 [95% CI, 1.58-3.52] vs 1.64 [95% CI, 1.16-2.31]), which was already 2-fold higher than diabetes prevalence in the studied community. Micro-CT of bony fragments found in the paravertebral tissue harvested during revision surgery revealed structural differences suggesting that newly formed bone in diabetic patients may be of compromised quality, as compared with that in nondiabetic patients. In conclusion, diabetes significantly increases the risk of unsuccessful lumbar spine fusion outcome requiring revision surgery. Diabetes predisposes to the degeneration of adjacent spine segments and pseudoarthrosis at the fusion sites, and affects the structure of newly formed bone needed to stabilize fusion., Competing Interests: All authors have no competing interests to declare., (© The Author(s) 2024. Published by Oxford University Press on behalf of the American Society for Bone and Mineral Research.)
- Published
- 2024
- Full Text
- View/download PDF
22. Osteocytes contribute via nuclear receptor PPAR-alpha to maintenance of bone and systemic energy metabolism.
- Author
-
Chougule A, Baroi S, Czernik PJ, Crowe E, Chang MR, Griffin PR, and Lecka-Czernik B
- Subjects
- Animals, Mice, Cells, Cultured, Male, Female, Signal Transduction, Mice, Knockout, Hematopoietic Stem Cells cytology, Cell Differentiation genetics, Age Factors, Gene Expression Profiling, Osteocytes metabolism, PPAR alpha genetics, PPAR alpha metabolism, Bone and Bones cytology, Bone and Bones metabolism, Energy Metabolism genetics
- Abstract
Introduction: The view that bone and energy metabolism are integrated by common regulatory mechanisms is broadly accepted and supported by multiple strands of evidence. This includes the well-characterized role of the PPARγ nuclear receptor, which is a common denominator in energy metabolism and bone metabolism. Little is known, however, about the role of PPARα nuclear receptor, a major regulator of lipid metabolism in other organs, in bone., Methods: A side-by-side comparative study of 5-15 mo old mice with global PPARα deficiency (α
KO ) and mice with osteocyte-specific PPARα deficiency (αOTKO ) in order to parse out the various activities of PPARα in the skeleton that are of local and systemic significance. This study included transcriptome analysis of PPARα-deficient osteocytes, and analyses of bone mass and bone microarchitecture, systemic energy metabolism with indirect calorimetry, and differentiation potential of hematopoietic and mesenchymal bone cell progenitors. These analyses were paired with in vitro studies of either intact or silenced for PPARα MLO-A5 cells to determine PPARα role in osteocyte bioenergetics., Results: In osteocytes, PPARα controls large number of transcripts coding for signaling and secreted proteins which may regulate bone microenvironment and peripheral fat metabolism. In addition, PPARα in osteocytes controls their bioenergetics and mitochondrial response to stress, which constitutes up to 40% of total PPARα contribution to the global energy metabolism. Similarly to αKO mice, the metabolic phenotype of αOTKO mice (both males and females) is age-dependent. In younger mice, osteocyte metabolism contributes positively to global energetics, however, with aging the high-energy phenotype reverts to a low-energy phenotype and obesity develops, suggesting a longitudinal negative effect of impaired lipid metabolism and mitochondrial dysfunction in osteocytes deficient in PPARα. However, bone phenotype was not affected in αOTKO mice except in the form of an increased volume of marrow adipose tissue in males. In contrast, global PPARα deficiency in αKO mice led to enlarged bone diameter with a proportional increase in number of trabeculae and enlarged marrow cavities; it also altered differentiation of hematopoietic and mesenchymal marrow cells toward osteoclast, osteoblast and adipocyte lineages, respectively., Discussion: PPARα role in bone is multileveled and complex. In osteocytes, PPARα controls the bioenergetics of these cells, which significantly contributes to systemic energy metabolism and their endocrine/paracrine function in controlling marrow adiposity and peripheral fat metabolism., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Chougule, Baroi, Czernik, Crowe, Chang, Griffin and Lecka-Czernik.)- Published
- 2023
- Full Text
- View/download PDF
23. Diabetes and Impaired Fracture Healing: A Narrative Review of Recent Literature.
- Author
-
Tanios M, Brickman B, Cage E, Abbas K, Smith C, Atallah M, Baroi S, and Lecka-Czernik B
- Subjects
- Glycation End Products, Advanced, Humans, Inflammation Mediators, Reactive Oxygen Species, Diabetes Mellitus, Type 2 complications, Fracture Healing physiology
- Abstract
Purpose of the Review: Diabetes mellitus is a chronic metabolic disorder commonly encountered in orthopedic patients. Both type 1 and type 2 diabetes mellitus increase fracture risk and impair fracture healing. This review examines complex etiology of impaired fracture healing in diabetes., Recent Findings: Recent findings point to several mechanisms leading to orthopedic complications in diabetes. Hyperglycemia and chronic inflammation lead to increased formation of advanced glycation end products and generation of reactive oxygen species, which in turn contribute to the disruption in osteoblast and osteoclast balance leading to decreased bone formation and heightening the risk of nonunion or delayed union as well as impaired fracture healing. The mechanisms attributing to this imbalance is secondary to an increase in pro-inflammatory mediators leading to premature resorption of callus cartilage and impaired bone formation due to compromised osteoblast differentiation and their apoptosis. Other mechanisms include disruption in the bone's microenvironment supporting different stages of healing process including hematoma and callus formation, and their resolution during bone remodeling phase. Complications of diabetes including peripheral neuropathy and peripheral vascular disease also contribute to the impairment of fracture healing. Certain diabetic drugs may have adverse effects on fracture healing. The pathophysiology of impaired fracture healing in diabetic patients is complex. This review provides an update of the most recent findings on how key mediators of bone healing are affected in diabetes., (© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
24. Reconstitution of the host holobiont in germ-free born male rats acutely increases bone growth and affects marrow cellular content.
- Author
-
Czernik PJ, Golonka RM, Chakraborty S, Yeoh BS, Abokor AA, Saha P, Yeo JY, Mell B, Cheng X, Baroi S, Tian Y, Patterson AD, Joe B, Vijay-Kumar M, and Lecka-Czernik B
- Subjects
- Adipocytes metabolism, Animals, Bone Density physiology, Cell Proliferation physiology, Chondrocytes metabolism, Coprophagia, Dysbiosis, Fatty Acids, Volatile analysis, Fatty Acids, Volatile metabolism, Feces microbiology, Male, RNA, Ribosomal, 16S genetics, Rats, Rats, Sprague-Dawley, Bacteria genetics, Bacteria metabolism, Bone Development physiology, Bone Marrow Cells metabolism, Gastrointestinal Microbiome genetics, Germ-Free Life, Host Microbial Interactions genetics, Osteogenesis physiology
- Abstract
Integration of microbiota in a host begins at birth and progresses during adolescence, forming a multidirectional system of physiological interactions. Here, we present an instantaneous effect of natural, bacterial gut colonization on the acceleration of longitudinal and radial bone growth in germ-free born, 7-wk-old male rats. Changes in bone mass and structure were analyzed after 10 days following the onset of colonization through cohousing with conventional rats and revealed unprecedented acceleration of bone accrual in cortical and trabecular compartments, increased bone tissue mineral density, improved proliferation and hypertrophy of growth plate chondrocytes, bone lengthening, and preferential deposition of periosteal bone in the tibia diaphysis. In addition, the number of small in size adipocytes increased, whereas the number of megakaryocytes decreased, in the bone marrow of conventionalized germ-free rats indicating that not only bone mass but also bone marrow environment is under control of gut microbiota signaling. The changes in bone status paralleled with a positive shift in microbiota composition toward short-chain fatty acids (SCFA)-producing microbes and a considerable increase in cecal SCFA concentrations, specifically butyrate. Furthermore, reconstitution of the host holobiont increased hepatic expression of IGF-1 and its circulating levels. Elevated serum levels of 25-hydroxy vitamin D and alkaline phosphatase pointed toward an active process of bone formation. The acute stimulatory effect on bone growth occurred independently of body mass increase. Overall, the presented model of conventionalized germ-free rats could be used to study microbiota-based therapeutics for combatting dysbiosis-related bone disorders.
- Published
- 2021
- Full Text
- View/download PDF
25. Report From the 6 th International Meeting on Bone Marrow Adiposity (BMA2020).
- Author
-
Scheller EL, McGee-Lawrence ME, and Lecka-Czernik B
- Subjects
- Hematopoiesis, Humans, Malnutrition, Neoplasms, Obesity, Adiposity, Bone Marrow metabolism
- Abstract
The 6
th International Meeting on Bone Marrow Adiposity (BMA) entitled "Marrow Adiposity: Bone, Aging, and Beyond" (BMA2020) was held virtually on September 9th and 10th , 2020. The mission of this meeting was to facilitate communication and collaboration among scientists from around the world who are interested in different aspects of bone marrow adiposity in health and disease. The BMA2020 meeting brought together 198 attendees from diverse research and clinical backgrounds spanning fields including bone biology, endocrinology, stem cell biology, metabolism, oncology, aging, and hematopoiesis. The congress featured an invited keynote address by Ormond MacDougald and ten invited speakers, in addition to 20 short talks, 35 posters, and several training and networking sessions. This report summarizes and highlights the scientific content of the meeting and the progress of the working groups of the BMA society (http://bma-society.org/)., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer WC declared a past collaboration with one of the authors ES to the handling editor., (Copyright © 2021 Scheller, McGee-Lawrence and Lecka-Czernik.)- Published
- 2021
- Full Text
- View/download PDF
26. PPARG in osteocytes controls sclerostin expression, bone mass, marrow adiposity and mediates TZD-induced bone loss.
- Author
-
Baroi S, Czernik PJ, Chougule A, Griffin PR, and Lecka-Czernik B
- Subjects
- Adaptor Proteins, Signal Transducing metabolism, Adiposity, Animals, Bone Marrow metabolism, Female, Glycoproteins metabolism, Intercellular Signaling Peptides and Proteins, Mice, Osteocytes metabolism, PPAR gamma genetics
- Abstract
The peroxisome proliferator activated receptor gamma (PPARG) nuclear receptor regulates energy metabolism and insulin sensitivity. In this study, we present novel evidence for an essential role of PPARG in the regulation of osteocyte function, and support for the emerging concept of the conjunction between regulation of energy metabolism and bone mass. We report that PPARG is essential for sclerostin production, a recently approved target to treat osteoporosis. Our mouse model of osteocyte-specific PPARG deletion (Dmp1
Cre Pparγflfl or γOTKO ) is characterized with increased bone mass and reduced bone marrow adiposity, which is consistent with upregulation of WNT signaling and increased bone forming activity of endosteal osteoblasts. An analysis of osteocytes derived from γOTKO and control mice showed an excellent correlation between PPARG and SOST/sclerostin at the transcript and protein levels. The 8 kb sequence upstream of Sost gene transcription start site possesses multiple PPARG binding elements (PPREs) with at least two of them binding PPARG with dynamics reflecting its activation with full agonist rosiglitazone and correlating with increased levels of Sost transcript and sclerostin protein expression (Pearson's r = 0.991, p = 0.001). Older γOTKO female mice are largely protected from TZD-induced bone loss providing proof of concept that PPARG in osteocytes can be pharmacologically targeted. These findings demonstrate that transcriptional activities of PPARG are essential for sclerostin expression in osteocytes and support consideration of targeting PPARG activities with selective modulators to treat osteoporosis., (Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
27. Single Nucleotide Polymorphism of Spp2 Confers Sex-Specific Effects on Blood Pressure and Bone Health.
- Author
-
Chakraborty S, Mell B, Nie Y, Cheng X, Galla S, Czernik P, Lecka-Czernik B, and Joe B
- Subjects
- Animals, Female, Male, Rats, Rats, Transgenic, Sex Factors, X-Ray Microtomography, Blood Pressure genetics, Bone Density genetics, Cancellous Bone diagnostic imaging, Phosphoproteins genetics, Polymorphism, Single Nucleotide
- Published
- 2020
- Full Text
- View/download PDF
28. Nonenzymatic and Trophic Activities of Carboxypeptidase E Regulate Bone Mass and Bioenergetics of Skeletal Stem Cells in Mice.
- Author
-
Chougule A, Kolli V, Baroi S, Ebraheim N, Czernik PJ, Loh YP, and Lecka-Czernik B
- Abstract
Bone and energy metabolism are integrated by common regulatory mechanisms. Carboxypeptidase E (CPE), also known as obesity susceptibility protein or neurotrophic factor-α1, is recognized for its function in processing prohormones, including proinsulin and pro-opiomelanocortin polypeptide. Independent of its enzymatic activity, CPE may also act as a secreted factor with divergent roles in neuroprotection and cancer growth; however, its role in the regulation of bone mass and skeletal cell differentiation is unknown. Male mice with global deficiency in CPE are characterized with profound visceral obesity, low bone mass in both appendicular and axial skeleton, and high volume of marrow fat. Interestingly, although metabolic deficit of CPE KO mice develops early in life, bone deficit develops in older age, suggesting that CPE bone-specific activities differ from its enzymatic activities. Indeed, mutated CPE knockin (mCPE KI) mice ectopically expressing CPE-E342Q, a mutated protein lacking enzymatic activity, develop the same obese phenotype and accumulate the same volume of marrow fat as CPE KO mice, but their bone mass is normal. In addition, differentiation of marrow hematopoietic cells toward tartrate-resistant acid phosphatase-positive multinucleated osteoclasts is highly increased in CPE KO mice, but normal in mCPE KI mice. Moreover, in murine skeletal stem cells, nonenzymatic trophic CPE has activated ERK signaling, increased cell proliferation and increased mitochondrial activity. Treatment of preosteoblastic cells with intact or mutated recombinant CPE led to a transient accumulation of small lipid droplets, increased oxidative phosphorylation, and increased cellular dependence on fatty acids as fuel for energy production. In human marrow aspirates, CPE expression increases up to 30-fold in osteogenic conditions. These findings suggest that nonenzymatic and trophic activities of CPE regulate bone mass, whereas marrow adiposity is controlled by CPE enzymatic activity. Thus, CPE can be positioned as a factor regulating simultaneously bone and energy metabolism through a combination of shared and distinct mechanisms. © 2020 The Authors. JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research © 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research., (© 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research.)
- Published
- 2020
- Full Text
- View/download PDF
29. Bone Marrow Adiposity- Special Edition.
- Author
-
Lecka-Czernik B and Rosen CJ
- Subjects
- Adipocytes cytology, Animals, Humans, Imaging, Three-Dimensional, Lipid Droplets metabolism, Adiposity physiology, Bone Marrow physiology
- Published
- 2019
- Full Text
- View/download PDF
30. Protein phosphatase PP5 controls bone mass and the negative effects of rosiglitazone on bone through reciprocal regulation of PPARγ (peroxisome proliferator-activated receptor γ) and RUNX2 (runt-related transcription factor 2).
- Author
-
Stechschulte LA, Ge C, Hinds TD Jr, Sanchez ER, Franceschi RT, and Lecka-Czernik B
- Published
- 2018
- Full Text
- View/download PDF
31. Marrow Fat-a New Target to Treat Bone Diseases?
- Author
-
Lecka-Czernik B, Baroi S, Stechschulte LA, and Chougule AS
- Subjects
- Adipose Tissue cytology, Bone Diseases metabolism, Bone Marrow Cells, Humans, Adipocytes metabolism, Adipose Tissue metabolism, Bone Diseases therapy, Bone Marrow metabolism, Energy Metabolism, Osteoblasts metabolism, Paracrine Communication
- Abstract
Purpose of Review: The goal of this review is to summarize recent findings on marrow adipose tissue (MAT) function and to discuss the possibility of targeting MAT for therapeutic purposes., Recent Findings: MAT is characterized with high heterogeneity which may suggest both that marrow adipocytes originate from multiple different progenitors and/or their phenotype is determined by skeletal location and environmental cues. Close relationship to osteoblasts and heterogeneity suggests that MAT consists of cells representing spectrum of phenotypes ranging from lipid-filled adipocytes to pre-osteoblasts. We propose a term of adiposteoblast for describing phenotypic spectrum of MAT. Manipulating with MAT activity in diseases where impairment in energy metabolism correlates with bone functional deficit, such as aging and diabetes, may be beneficial for both. Paracrine activities of MAT might be considered for treatment of bone diseases. MAT has unrecognized potential, either beneficial or detrimental, to regulate bone homeostasis in physiological and pathological conditions. More research is required to harness this potential for therapeutic purposes.
- Published
- 2018
- Full Text
- View/download PDF
32. Injectable nanosilica-chitosan microparticles for bone regeneration applications.
- Author
-
Gaihre B, Lecka-Czernik B, and Jayasuriya AC
- Subjects
- Animals, Cells, Cultured, Mice, Osteoblasts cytology, Silicon Dioxide, Bone Regeneration, Chitosan analogs & derivatives, Nanoparticles, Tissue Scaffolds chemistry
- Abstract
This study was aimed at assessing the effects of silica nanopowder incorporation into chitosan-tripolyphosphate microparticles with the ultimate goal of improving their osteogenic properties. The microparticles were prepared by simple coacervation technique and silica nanopowder was added at 0% (C), 2.5% (S1), 5% (S2) and 10% (S3) (w/w) to chitosan. We observed that this simple incorporation of silica nanopowder improved the growth and proliferation of osteoblasts along the surface of the microparticles. In addition, the composite microparticles also showed the increased expression of alkaline phosphatase and osteoblast specific genes. We observed a significant increase ( p < 0.05) in the expression of alkaline phosphatase by the cells growing on all sample groups compared to the control (C) groups at day 14. The morphological characterization of these microparticles through scanning electron microscopy showed that these microparticles were well suited to be used as the injectable scaffolds with perfectly spherical shape and size. The incorporation of silica nanopowder altered the nano-roughness of the microparticles as observed through atomic force microscopy scans with roughness values going down from C to S3. The results in this study, taken together, show the potential of chitosan-tripolyphosphate-silica nanopowder microparticles for improved bone regeneration applications.
- Published
- 2018
- Full Text
- View/download PDF
33. Marrow Adipose Tissue: Skeletal Location, Sexual Dimorphism, and Response to Sex Steroid Deficiency.
- Author
-
Lecka-Czernik B, Stechschulte LA, Czernik PJ, Sherman SB, Huang S, and Krings A
- Abstract
Marrow adipose tissue (MAT) is unique with respect to origin, metabolism, and function. MAT is characterized with high heterogeneity which correlates with skeletal location and bone metabolism. This fat depot is also highly sensitive to various hormonal, environmental, and pharmacologic cues to which it responds with changes in volume and/or metabolic phenotype. We have demonstrated previously that MAT has characteristics of both white (WAT) and brown (BAT)-like or beige adipose tissue, and that beige phenotype is attenuated with aging and in diabetes. Here, we extended our analysis by comparing MAT phenotype in different locations within a tibia bone of mature C57BL/6 mice and with respect to the presence of sex steroids in males and females. We report that MAT juxtaposed to trabecular bone of proximal tibia (pMAT) is characterized by elevated expression of beige fat markers including Ucp1, HoxC9, Prdm16, Tbx1 , and Dio2 , when compared with MAT located in distal tibia (dMAT). There is also a difference in tissue organization with adipocytes in proximal tibia being dispersed between trabeculae, while adipocytes in distal tibia being densely packed. Higher trabecular bone mass (BV/TV) in males correlates with lower pMAT volume and higher expression of beige markers in the same location, when compared with females. However, there is no sexual divergence in the volume and transcriptional profile of dMAT. A removal of ovaries in females resulted in decreased cortical bone mass and increased volume of both pMAT and dMAT, as well as volume of gonadal WAT (gWAT). Increase in pMAT volume was associated with marked increase in Fabp4 and Adiponectin expression and relative decrease in beige fat gene markers. A removal of testes in males resulted in cortical and trabecular bone loss and the tendency to increased volume of both pMAT and dMAT, despite a loss of gWAT. Orchiectomy did not affect the expression of white and beige adipocyte gene markers. In conclusion, expression profile of beige adipocyte gene markers correlates with skeletal location of active bone remodeling and higher BV/TV, however bone loss resulted from sex steroid deficiency is not proportional to MAT expansion at the same skeletal location.
- Published
- 2017
- Full Text
- View/download PDF
34. Diabetes, bone and glucose-lowering agents: basic biology.
- Author
-
Lecka-Czernik B
- Subjects
- Animals, Biomarkers metabolism, Blood Flow Velocity, Blood Glucose analysis, Bone Density, Bone and Bones physiology, Diabetes Mellitus, Type 1 physiopathology, Diabetes Mellitus, Type 2 physiopathology, Fractures, Bone drug therapy, Fractures, Bone metabolism, Glycation End Products, Advanced metabolism, Homeostasis, Humans, Insulin chemistry, Metformin therapeutic use, Mice, Microcirculation, Muscles metabolism, Osteoporosis drug therapy, Stem Cell Niche drug effects, Sulfonylurea Compounds therapeutic use, Bone and Bones drug effects, Diabetes Mellitus, Type 1 drug therapy, Diabetes Mellitus, Type 2 drug therapy, Hypoglycemic Agents therapeutic use
- Abstract
Skeletal fragility often accompanies diabetes and does not appear to correlate with low bone mass or trauma severity in individuals with diabetes. Instead (and in contrast to those with osteoporotic bone disease), bone remodelling and bone turnover are compromised in both type 1 and type 2 diabetes, contributing to defective bone material quality. This review is one of a pair discussing the relationship between diabetes, bone and glucose-lowering agents; an accompanying review is provided in this issue of Diabetologia by Ann Schwartz (DOI: 10.1007/s00125-017-4283-6 ). This review presents basic science evidence that, alongside other organs, bone is affected in diabetes via impairments in glucose metabolism, toxic effects of glucose oxidative derivatives (advance glycation end-products [AGEs]), and via impairments in bone microvascular function and muscle endocrine function. The cellular and molecular basis for the effects of diabetes on bone are discussed, as is the impact of diabetes on the stem cell niche and fracture healing. Furthermore, the safety of clinically approved glucose-lowering therapies and the possibility of developing a single therapy that would be beneficial for both insulin sensitisation and diabetes bone syndrome are outlined.
- Published
- 2017
- Full Text
- View/download PDF
35. Reciprocal regulation of PPARγ and RUNX2 activities in marrow mesenchymal stem cells: Fine balance between p38 MAPK and Protein Phosphatase 5.
- Author
-
Stechschulte LA and Lecka-Czernik B
- Abstract
Purpose of Review: Post-translational modifications (PTMs), specifically serine phosphorylation, are essential for determination and tuning up an activity of many proteins, including those that are involved in the control of gene transcription. Transcription factors PPARγ2 and RUNX2 are essential for mesenchymal stem cell (MSC) commitment to either adipocyte or osteoblast lineage. This review is summarizing current knowledge how serine phosphorylation PTMs regulate activities of both transcription factors and MSCs lineage commitment., Recent Finding: Both PPARγ2 and RUNX2 transcriptional activities are regulated by similar PTMs, however with an opposite outcome. The same p38 MAPK mediates serine phosphorylation that leads to activation of RUNX2 and inactivation of PPARγ2. The process of protein phosphorylation is balanced with a process of protein dephosphorylation. Protein phosphatase 5 simultaneously dephosphorylates both proteins, which results in activation of PPARγ2 and inactivation of RUNX2., Summary: This review provides a summary of the "yinyang" fine-tuned mechanism by which p38 MAPK and PP5 regulate MSCs lineage commitment., Competing Interests: Compliance with Ethical Standards: Conflict of Interest: Lance A. Stechschulte and BeataLecka-Czernik each declare no potential conflicts of interest.
- Published
- 2017
- Full Text
- View/download PDF
36. Protein Phosphatase PP5 Controls Bone Mass and the Negative Effects of Rosiglitazone on Bone through Reciprocal Regulation of PPARγ (Peroxisome Proliferator-activated Receptor γ) and RUNX2 (Runt-related Transcription Factor 2).
- Author
-
Stechschulte LA, Ge C, Hinds TD Jr, Sanchez ER, Franceschi RT, and Lecka-Czernik B
- Subjects
- Active Transport, Cell Nucleus drug effects, Active Transport, Cell Nucleus genetics, Animals, Body Weight genetics, Cell Nucleus genetics, Core Binding Factor Alpha 1 Subunit genetics, Glycoproteins genetics, Male, Mesenchymal Stem Cells metabolism, Mice, Mice, Knockout, PPAR gamma genetics, Rosiglitazone, Body Weight drug effects, Bone and Bones metabolism, Cell Nucleus metabolism, Core Binding Factor Alpha 1 Subunit metabolism, Glycoproteins metabolism, PPAR gamma metabolism, Thiazolidinediones pharmacology
- Abstract
Peroxisome proliferator-activated receptor γ (PPARγ) and runt-related transcription factor 2 (RUNX2) are key regulators of mesenchymal stem cell (MSC) differentiation toward adipocytes and osteoblasts, respectively. Post-translational modifications of these factors determine their activities. Dephosphorylation of PPARγ at Ser-112 is required for its adipocytic activity, whereas phosphorylation of RUNX2 at serine 319 (Ser-319) promotes its osteoblastic activity. Here we show that protein phosphatase 5 (PP5) reciprocally regulates each receptor by targeting each serine. Mice deficient in PP5 phosphatase have increased osteoblast numbers and high bone formation, which results in high bone mass in the appendicular and axial skeleton. This is associated with a substantial decrease in lipid-containing marrow adipocytes. Indeed, in the absence of PP5 the MSC lineage allocation is skewed toward osteoblasts and away from lipid accumulating adipocytes, although an increase in beige adipocyte gene expression is observed. In the presence of rosiglitazone, PP5 translocates to the nucleus, binds to PPARγ and RUNX2, and dephosphorylates both factors, resulting in activation of PPARγ adipocytic and suppression of RUNX2 osteoblastic activities. Moreover, shRNA knockdown of PP5 results in cells refractory to rosiglitazone treatment. Lastly, mice deficient in PP5 are resistant to the negative effects of rosiglitazone on bone, which in wild type animals causes a 50% decrease in trabecular bone mass. In conclusion, PP5 is a unique phosphatase reciprocally regulating PPARγ and RUNX2 activities in marrow MSC., (© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.)
- Published
- 2016
- Full Text
- View/download PDF
37. FKBP51 Null Mice Are Resistant to Diet-Induced Obesity and the PPARγ Agonist Rosiglitazone.
- Author
-
Stechschulte LA, Qiu B, Warrier M, Hinds TD Jr, Zhang M, Gu H, Xu Y, Khuder SS, Russo L, Najjar SM, Lecka-Czernik B, Yong W, and Sanchez ER
- Subjects
- Adiposity, Animals, Energy Metabolism, Fatty Liver etiology, Intra-Abdominal Fat cytology, Lipids blood, Male, Mice, Knockout, Rosiglitazone, Thiazolidinediones, Weight Gain, Glucose Intolerance, Lipid Metabolism, Obesity etiology, PPAR gamma physiology, Tacrolimus Binding Proteins physiology
- Abstract
FK506-binding protein-51 (FKBP51) is a molecular cochaperone recently shown to be a positive regulator of peroxisome proliferator-activated receptor (PPAR)γ, the master regulator of adipocyte differentiation and function. In cellular models of adipogenesis, loss of FKBP51 not only reduced PPARγ activity but also reduced lipid accumulation, suggesting that FKBP51 knock-out (KO) mice might have insufficient development of adipose tissue and lipid storage ability. This model was tested by examining wild-type (WT) and FKBP51-KO mice under regular and high-fat diet conditions. Under both diets, FKBP51-KO mice were resistant to weight gain, hepatic steatosis, and had greatly reduced white adipose tissue (WAT) but higher amounts of brown adipose tissue. Under high-fat diet, KO mice were highly resistant to adiposity and exhibited reduced plasma lipids and elevated glucose and insulin tolerance. Profiling of perigonadal and sc WAT revealed elevated expression of brown adipose tissue lineage genes in KO mice that correlated increased energy expenditure and a shift of substrate oxidation to carbohydrates, as measured by indirect calorimetry. To directly test PPARγ involvement, WT and KO mice were fed rosiglitazone agonist. In WT mice, rosiglitazone induced whole-body weight gain, increased WAT mass, a shift of substrate oxidation to lipids, and elevated expression of PPARγ-regulated lipogenic genes in WAT. In contrast, KO mice had reduced rosiglitazone responses for these parameters. Our results identify FKBP51 as an important regulator of PPARγ in WAT and as a potential new target in the treatment of obesity and diabetes.
- Published
- 2016
- Full Text
- View/download PDF
38. Skeletal Metabolism, Fracture Risk, and Fracture Outcomes in Type 1 and Type 2 Diabetes.
- Author
-
Sellmeyer DE, Civitelli R, Hofbauer LC, Khosla S, Lecka-Czernik B, and Schwartz AV
- Subjects
- Diabetes Mellitus, Type 1 metabolism, Diabetes Mellitus, Type 2 metabolism, Fractures, Bone metabolism, Humans, Risk Factors, Bone Density physiology, Bone and Bones metabolism, Diabetes Mellitus, Type 1 complications, Diabetes Mellitus, Type 2 complications, Fractures, Bone etiology
- Abstract
Fracture risk is significantly increased in both type 1 and type 2 diabetes, and individuals with diabetes experience worse fracture outcomes than normoglycemic individuals. Factors that increase fracture risk include lower bone mass in type 1 diabetes and compromised skeletal quality and strength despite preserved bone density in type 2 diabetes, as well as the effects of comorbidities such as diabetic macro- and microvascular complications. In this Perspective, we assess the developing scientific knowledge regarding the epidemiology and pathophysiology of skeletal fragility in patients with diabetes and the emerging data on the prediction, treatment, and outcomes of fractures in individuals with type 1 and type 2 diabetes., (© 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.)
- Published
- 2016
- Full Text
- View/download PDF
39. High-resolution mapping of a novel rat blood pressure locus on chromosome 9 to a region containing the Spp2 gene and colocalization of a QTL for bone mass.
- Author
-
Nie Y, Kumarasamy S, Waghulde H, Cheng X, Mell B, Czernik PJ, Lecka-Czernik B, and Joe B
- Subjects
- Alleles, Animals, Animals, Congenic genetics, Chromosome Mapping methods, Genetic Linkage genetics, Humans, Hypertension genetics, Male, Rats, Rats, Inbred Dahl, Rats, Inbred SHR genetics, Rats, Inbred WKY, Sodium Chloride, Dietary administration & dosage, Blood Pressure genetics, Bone and Bones metabolism, Chromosomes, Human, Pair 9 genetics, Phosphoproteins genetics, Quantitative Trait Loci genetics
- Abstract
Through linkage analysis of the Dahl salt-sensitive (S) rat and the spontaneously hypertensive rat (SHR), a blood pressure (BP) quantitative trait locus (QTL) was previously located on rat chromosome 9. Subsequent substitution mapping studies of this QTL revealed multiple BP QTLs within the originally identified logarithm of odds plot by linkage analysis. The focus of this study was on a 14.39 Mb region, the distal portion of which remained unmapped in our previous studies. High-resolution substitution mapping for a BP QTL in the setting of a high-salt diet indicated that an SHR-derived congenic segment of 787.9 kb containing the gene secreted phosphoprotein-2 (Spp2) lowered BP and urinary protein excretion. A nonsynonymous G/T polymorphism in the Spp2 gene was detected between the S and S.SHR congenic rats. A survey of 45 strains showed that the T allele was rare, being detected only in some substrains of SHR and WKY. Protein modeling prediction through SWISSPROT indicated that the predicted protein product of this variant was significantly altered. Importantly, in addition to improved cardiovascular and renal function, high salt-fed congenic animals carrying the SHR T variant of Spp2 had significantly lower bone mass and altered bone microarchitecture. Total bone volume and volume of trabecular bone, cortical thickness, and degree of mineralization of cortical bone were all significantly reduced in congenic rats. Our study points to opposing effects of a congenic segment containing the prioritized candidate gene Spp2 on BP and bone mass., (Copyright © 2016 the American Physiological Society.)
- Published
- 2016
- Full Text
- View/download PDF
40. Sweet and brittle - Diabetes mellitus and the skeleton.
- Author
-
Hofbauer LC, Lecka-Czernik B, and Seibel MJ
- Subjects
- Bone Density physiology, Diabetes Mellitus diagnosis, Diabetes Mellitus metabolism, Fractures, Bone diagnosis, Fractures, Bone metabolism, Humans, Osteoporosis diagnosis, Osteoporosis metabolism, Diabetes Mellitus epidemiology, Fractures, Bone epidemiology, Osteoporosis epidemiology
- Published
- 2016
- Full Text
- View/download PDF
41. Orthopedic complications in diabetes.
- Author
-
Gehling DJ, Lecka-Czernik B, and Ebraheim NA
- Subjects
- Animals, Bone Diseases diagnosis, Diabetes Complications diagnosis, Diabetes Mellitus diagnosis, Fractures, Bone diagnosis, Humans, Bone Diseases epidemiology, Diabetes Complications epidemiology, Diabetes Mellitus epidemiology, Fractures, Bone epidemiology
- Abstract
Diabetes is associated with a number of lower extremity orthopedic conditions and complications including fractures, Charcot neuroarthropathy, plantar ulcers, and infection. These complications are of significant clinical concern in terms of morbidity, mortality, and socioeconomic costs. A review of each condition is discussed, with particular emphasis on the clinical importance, diagnostic considerations, and orthopedic treatment recommendations. The goal of the article is to provide a clinical picture of the challenges that orthopedic surgeons confront, and highlight the need for specific clinical guidelines in diabetic patients., (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
42. Effects of diabetes drugs on the skeleton.
- Author
-
Meier C, Schwartz AV, Egger A, and Lecka-Czernik B
- Subjects
- Animals, Blood Glucose drug effects, Blood Glucose metabolism, Diabetes Mellitus metabolism, Dipeptidyl-Peptidase IV Inhibitors adverse effects, Fractures, Bone metabolism, Glucagon-Like Peptide 1 antagonists & inhibitors, Glucagon-Like Peptide 1 metabolism, Humans, Insulin-Like Growth Factor I antagonists & inhibitors, Insulin-Like Growth Factor I metabolism, Metformin adverse effects, Diabetes Mellitus drug therapy, Diabetes Mellitus epidemiology, Fractures, Bone chemically induced, Fractures, Bone epidemiology, Hypoglycemic Agents adverse effects
- Abstract
Type 2 diabetes is associated with increased fracture risk and the mechanisms underlying the detrimental effects of diabetes on skeletal health are only partially understood. Antidiabetic drugs are indispensable for glycemic control in most type 2 diabetics, however, they may, at least in part, modulate fracture risk in exposed patients. Preclinical and clinical data clearly demonstrate an unfavorable effect of thiazolidinediones on the skeleton with impaired osteoblast function and activated osteoclastogenesis. The negative effect of thiazolidinediones on osteoblastogenesis includes decreased activity of osteoblast-specific transcription factors (e.g. Runx2, Dlx5, osterix) and decreased activity of osteoblast-specific signaling pathways (e.g. Wnt, TGF-β/BMP, IGF-1). In contrast, metformin has a positive effect on osteoblast differentiation due to increased activity of Runx2 via the AMPK/USF-1/SHP regulatory cascade resulting in a neutral or potentially protective effect on bone. Recently marketed antidiabetic drugs include incretin-based therapies (GLP-1 receptor agonists, DPP-4 inhibitors) and sodium-glucose co-transporter 2 (SGLT2)-inhibitors. Preclinical studies indicate that incretins (GIP, GLP-1, and GLP-2) play an important role in the regulation of bone turnover. Clinical safety data are limited, however, meta-analyses of trials investigating the glycemic-lowering effect of both, GLP-1 receptor agonists and DPP4-inhibitors, suggest a neutral effect of incretin-based therapies on fracture risk. For SGLT2-inhibitors recent data indicate that due to their mode of action they may alter calcium and phosphate homeostasis (secondary hyperparathyroidism induced by increased phosphate reabsorption) and thereby potentially affect bone mass and fracture risk. Clinical studies are needed to elucidate the effect of SGLT2-inhibitors on bone metabolism. Meanwhile SGLT2-inhibitors should be used with caution in patients with high fracture risk, which is specifically true for the use of thiazolidinediones., (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
43. Skeletal integration of energy homeostasis: Translational implications.
- Author
-
Lecka-Czernik B and Rosen CJ
- Subjects
- Adipose Tissue, Brown metabolism, Animals, Humans, Adipocytes metabolism, Bone Density physiology, Diabetes Mellitus, Type 2 metabolism, Energy Metabolism physiology, Homeostasis physiology, Translational Research, Biomedical trends
- Abstract
New evidence has recently emerged defining a close relationship between fat and bone metabolism. Adipose tissue is one of the largest organs in the body but its functions vary by location and origin. Adipocytes can act in an autocrine manner to regulate energy balance by sequestering triglycerides and then, depending on demand, releasing fatty acids through lipolysis for energy utilization, and in some cases through uncoupling protein 1 for generating heat. Adipose tissue can also act in an endocrine or paracrine manner by releasing adipokines that modulate the function of other organs. Bone is one of those target tissues, although recent evidence has emerged that the skeleton reciprocates by releasing its own factors that modulate adipose tissue and beta cells in the pancreas. Therefore, it is not surprising that these energy-modulating tissues are controlled by a central regulatory mechanism, primarily the sympathetic nervous system. Disruption in this complex regulatory circuit and its downstream tissues is manifested in a wide range of metabolic disorders, for which the most prevalent is type 2 diabetes mellitus. The aim of this review is to summarize our knowledge of common determinants in the bone and adipose function and the translational implications of recent work in this emerging field., (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
44. Energy Excess, Glucose Utilization, and Skeletal Remodeling: New Insights.
- Author
-
Lecka-Czernik B and Rosen CJ
- Subjects
- Adipose Tissue metabolism, Adipose Tissue pathology, Animals, Bone Diseases, Metabolic pathology, Diabetes Mellitus pathology, Humans, Insulin metabolism, Insulin Resistance, Insulin-Secreting Cells metabolism, Insulin-Secreting Cells pathology, Obesity metabolism, Obesity pathology, Bone Diseases, Metabolic metabolism, Bone Remodeling, Diabetes Mellitus metabolism, Energy Metabolism, Glucose metabolism
- Abstract
Skeletal complications have recently been recognized as another of the several comorbidities associated with diabetes. Clinical studies suggest that disordered glucose and lipid metabolism have a profound effect on bone. Diabetes-related changes in skeletal homeostasis result in a significant increased risk of fractures, although the pathophysiology may differ from postmenopausal osteoporosis. Efforts to understand the underlying mechanisms of diabetic bone disease have focused on the direct interaction of adipose tissue with skeletal remodeling and the potential influence of glucose utilization and energy uptake on these processes. One aspect that has emerged recently is the major role of the central nervous system in whole-body metabolism, bone turnover, adipose tissue remodeling, and beta cell secretion of insulin. Importantly, the skeleton contributes to the metabolic balance inherent in physiologic states. New animal models have provided the insights necessary to begin to dissect the effects of obesity and insulin resistance on the acquisition and maintenance of bone mass. In this Perspective, we focus on potential mechanisms that underlie the complex interactions between adipose tissue and skeletal turnover by focusing on the clinical evidence and on preclinical studies indicating that glucose intolerance may have a significant impact on the skeleton. In addition, we raise fundamental questions that need to be addressed in future studies to resolve the conundrum associated with glucose intolerance, obesity, and osteoporosis., (© 2015 American Society for Bone and Mineral Research.)
- Published
- 2015
- Full Text
- View/download PDF
45. Bone and fat: a relationship of different shades.
- Author
-
Lecka-Czernik B and Stechschulte LA
- Subjects
- Adipose Tissue cytology, Animals, Bone and Bones cytology, Humans, Models, Biological, Adipose Tissue physiology, Bone Remodeling physiology, Bone and Bones physiology, Energy Metabolism physiology, Homeostasis physiology
- Abstract
Environmental and behavioral changes which occurred over the last century led simultaneously to a remarkable increase in human lifespan and to the development of health problems associated with functional impairment of organs either regulating or dependent on balanced energy metabolism. Diseases such as diabetes, obesity and osteoporosis are prevalent in our society and pose major challenges with respect to the overall health and economy. Therefore, better understanding of regulatory axes between bone and fat may provide the basis for development of strategies which will treat these diseases simultaneously and improve health and life quality of elderly., (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
46. Partial agonist, telmisartan, maintains PPARγ serine 112 phosphorylation, and does not affect osteoblast differentiation and bone mass.
- Author
-
Kolli V, Stechschulte LA, Dowling AR, Rahman S, Czernik PJ, and Lecka-Czernik B
- Subjects
- Animals, Antihypertensive Agents pharmacology, Bone and Bones cytology, Bone and Bones metabolism, Cell Line, Mice, Osteoblasts cytology, Osteoblasts metabolism, PPAR gamma agonists, Phosphorylation drug effects, Signal Transduction drug effects, Telmisartan, Benzimidazoles pharmacology, Benzoates pharmacology, Bone and Bones drug effects, Osteoblasts drug effects, Osteogenesis drug effects, PPAR gamma metabolism
- Abstract
Peroxisome proliferator activated receptor gamma (PPARγ) controls both glucose metabolism and an allocation of marrow mesenchymal stem cells (MSCs) toward osteoblast and adipocyte lineages. Its activity is determined by interaction with a ligand which directs posttranscriptional modifications of PPARγ protein including dephosphorylation of Ser112 and Ser273, which results in acquiring of pro-adipocytic and insulin-sensitizing activities, respectively. PPARγ full agonist TZD rosiglitazone (ROSI) decreases phosphorylation of both Ser112 and Ser273 and its prolonged use causes bone loss in part due to diversion of MSCs differentiation from osteoblastic toward adipocytic lineage. Telmisartan (TEL), an anti-hypertensive drug from the class of angiotensin receptor blockers, also acts as a partial PPARγ agonist with insulin-sensitizing and a weak pro-adipocytic activity. TEL decreased S273pPPARγ and did not affect S112pPPARγ levels in a model of marrow MSC differentiation, U-33/γ2 cells. In contrast to ROSI, TEL did not affect osteoblast phenotype and actively blocked ROSI-induced anti-osteoblastic activity and dephosphorylation of S112pPPARγ. The effect of TEL on bone was tested side-by-side with ROSI. In contrast to ROSI, TEL administration did not affect bone mass and bone biomechanical properties measured by micro-indentation method and did not induce fat accumulation in bone, and it partially protected from ROSI-induced bone loss. In addition, TEL induced "browning" of epididymal white adipose tissue marked by increased expression of UCP1, FoxC2, Wnt10b and IGFBP2 and increased overall energy expenditure. These studies point to the complexity of mechanisms by which PPARγ acquires anti-osteoblastic and pro-adipocytic activities and suggest an importance of Ser112 phosphorylation status as being a part of the mechanism regulating this process. These studies showed that TEL acts as a full PPARγ agonist for insulin-sensitizing activity and as a partial agonist/partial antagonist for pro-adipocytic and anti-osteoblastic activities. They also suggest a relationship between PPARγ fat "browning" activity and a lack of anti-osteoblastic activity.
- Published
- 2014
- Full Text
- View/download PDF
47. An overview of recent advances in designing orthopedic and craniofacial implants.
- Author
-
Mantripragada VP, Lecka-Czernik B, Ebraheim NA, and Jayasuriya AC
- Subjects
- Biocompatible Materials pharmacology, Face, Humans, Orthopedics, Prostheses and Implants, Prosthesis Design trends, Skull physiology
- Abstract
Great deal of research is still going on in the field of orthopedic and craniofacial implant development to resolve various issues being faced by the industry today. Despite several disadvantages of the metallic implants, they continue to be used, primarily because of their superior mechanical properties. In order to minimize the harmful effects of the metallic implants and its by-products, several modifications are being made to these materials, for instance nickel-free stainless steel, cobalt-chromium and titanium alloys are being introduced to eliminate the toxic effects of nickel being released from the alloys, introduce metallic implants with lower modulus, reduce the cost of these alloys by replacing rare elements with less expensive elements etc. New alloys like tantalum, niobium, zirconium, and magnesium are receiving attention given their satisfying mechanical and biological properties. Non-oxide ceramics like silicon nitride and silicon carbide are being currently developed as a promising implant material possessing a combination of properties such as good wear and corrosion resistance, increased ductility, good fracture and creep resistance, and relatively high hardness in comparison to alumina. Polymer/magnesium composites are being developed to improve mechanical properties as well as retain polymer's property of degradation. Recent advances in orthobiologics are proving interesting as well. This paper thus deals with the latest improvements being made to the existing implant materials and includes new materials being introduced in the field of biomaterials., (Copyright © 2013 Wiley Periodicals, Inc.)
- Published
- 2013
- Full Text
- View/download PDF
48. Inducible brown adipose tissue, or beige fat, is anabolic for the skeleton.
- Author
-
Rahman S, Lu Y, Czernik PJ, Rosen CJ, Enerback S, and Lecka-Czernik B
- Subjects
- Adaptor Proteins, Signal Transducing, Adipocytes metabolism, Anabolic Agents metabolism, Animals, Bone and Bones cytology, Culture Media, Conditioned pharmacology, Forkhead Transcription Factors genetics, Forkhead Transcription Factors metabolism, Gene Expression, Glycoproteins genetics, Glycoproteins metabolism, Immunohistochemistry, Insulin-Like Growth Factor Binding Protein 2 genetics, Insulin-Like Growth Factor Binding Protein 2 metabolism, Intercellular Signaling Peptides and Proteins, Mice, Mice, Transgenic, Osteoblasts drug effects, Osteocytes drug effects, Phosphorylation, RANK Ligand genetics, RANK Ligand metabolism, Reverse Transcriptase Polymerase Chain Reaction, Wnt Proteins genetics, Wnt Proteins metabolism, beta Catenin genetics, beta Catenin metabolism, Adipose Tissue, Brown metabolism, Bone and Bones metabolism, Osteoblasts metabolism, Osteocytes metabolism
- Abstract
It is known that insulin resistance and type 2 diabetes mellitus are associated with increased fractures and that brown adipose tissue (BAT) counteracts many if not all of the symptoms associated with type 2 diabetes. By the use of FoxC2(AD)(+/Tg) mice, a well-established model for induction of BAT, or beige fat, we present data extending the beneficial action of beige fat to also include a positive effect on bone. FoxC2(AD)(+/Tg) mice are lean and insulin-sensitive and have high bone mass due to increased bone formation associated with high bone turnover. Inducible BAT is linked to activation of endosteal osteoblasts whereas osteocytes have decreased expression of the Sost transcript encoding sclerostin and elevated expression of Rankl. Conditioned media (CM) collected from forkhead box c2 (FOXC2)-induced beige adipocytes activated the osteoblast phenotype and increased levels of phospho-AKT and β-catenin in recipient cells. In osteocytes, the same media decreased Sost expression. Immunodepletion of CM with antibodies against wingless related MMTV integration site 10b (WNT10b) and insulin-like growth factor binding protein 2 (IGFBP2) resulted in the loss of pro-osteoblastic activity, and the loss of increase in the levels of phospho-AKT and β-catenin. Conversely, CM derived from cells overexpressing IGFBP2 or WNT10b restored osteoblastic activity in recipient cells. In conclusion, beige fat secretes endocrine/paracrine activity that is beneficial for the skeleton.
- Published
- 2013
- Full Text
- View/download PDF
49. Polycaprolactone nanofiber interspersed collagen type-I scaffold for bone regeneration: a unique injectable osteogenic scaffold.
- Author
-
Baylan N, Bhat S, Ditto M, Lawrence JG, Lecka-Czernik B, and Yildirim-Ayan E
- Subjects
- Animals, Biocompatible Materials chemistry, Bone Regeneration, Bone and Bones metabolism, Calcium chemistry, Cell Line, Cell Proliferation, Cell Survival, Collagen Type I administration & dosage, Extracellular Matrix metabolism, Materials Testing, Mice, Osteoblasts cytology, Osteogenesis, Phenotype, Polymethyl Methacrylate chemistry, Syringes, Tissue Engineering methods, Collagen administration & dosage, Collagen chemistry, Nanofibers chemistry, Polyesters chemistry, Tissue Scaffolds chemistry
- Abstract
There is an increasing demand for an injectable cell coupled three-dimensional (3D) scaffold to be used as bone fracture augmentation material. To address this demand, a novel injectable osteogenic scaffold called PN-COL was developed using cells, a natural polymer (collagen type-I), and a synthetic polymer (polycaprolactone (PCL)). The injectable nanofibrous PN-COL is created by interspersing PCL nanofibers within pre-osteoblast cell embedded collagen type-I. This simple yet novel and powerful approach provides a great benefit as an injectable bone scaffold over other non-living bone fracture stabilization polymers, such as polymethylmethacrylate and calcium content resin-based materials. The advantages of injectability and the biomimicry of collagen was coupled with the structural support of PCL nanofibers, to create cell encapsulated injectable 3D bone scaffolds with intricate porous internal architecture and high osteoconductivity. The effects of PCL nanofiber inclusion within the cell encapsulated collagen matrix has been evaluated for scaffold size retention and osteocompatibility, as well as for MC3T3-E1 cells osteogenic activity. The structural analysis of novel bioactive material proved that the material is chemically stable enough in an aqueous solution for an extended period of time without using crosslinking reagents, but it is also viscous enough to be injected through a syringe needle. Data from long-term in vitro proliferation and differentiation data suggests that novel PN-COL scaffolds promote the osteoblast proliferation, phenotype expression, and formation of mineralized matrix. This study demonstrates for the first time the feasibility of creating a structurally competent, injectable, cell embedded bone tissue scaffold. Furthermore, the results demonstrate the advantages of mimicking the hierarchical architecture of native bone with nano- and micro-size formation through introducing PCL nanofibers within macron-size collagen fibers and in promoting osteoblast phenotype progression for bone regeneration.
- Published
- 2013
- Full Text
- View/download PDF
50. IGFBP-2 is a negative predictor of cold-induced brown fat and bone mineral density in young non-obese women.
- Author
-
Bredella MA, Fazeli PK, Lecka-Czernik B, Rosen CJ, and Klibanski A
- Subjects
- Absorptiometry, Photon, Adult, Female, Humans, Insulin-Like Growth Factor I metabolism, Positron-Emission Tomography, Young Adult, Adipose Tissue, Brown metabolism, Bone Density physiology, Cold Temperature, Insulin-Like Growth Factor Binding Protein 2 metabolism
- Abstract
Recent studies have shown a positive correlation between brown adipose tissue (BAT) and bone mineral density (BMD). However, mechanisms underlying this relationship are unknown. Insulin-like growth factor 1 (IGF-1) is an important regulator of stem cell differentiation promoting bone formation. IGF binding protein 2 (IGFBP-2) binds IGF-1 in the circulation and has been reported to inhibit bone formation in humans. IGF-1 is also a crucial regulator of brown adipocyte differentiation. We hypothesized that IGFBP-2 is a negative and IGF-1 a positive regulator of BAT-mediated osteoblastogenesis. We therefore investigated a cohort of 15 women (mean age 27.7±5.7years): 5 with anorexia nervosa (AN) in whom IGF-1 levels were low due to starvation, 5 recovered AN (AN-R), and 5 women of normal weight. All subjects underwent assessment of cold-activated BAT by PET/CT, BMD of the spine, hip, femoral neck, and total body by DXA, thigh muscle area by MRI, IGF-1 and IGFBP-2. There was a positive correlation between BAT and BMD and an inverse association between IGFBP-2 and both BAT and BMD. There was no association between IGF-1 and BAT. We show for the first time that IGFBP-2 is a negative predictor of cold-induced BAT and BMD in young non-obese women, suggesting that IGFBP-2 may serve as a regulator of BAT-mediated osteoblastogenesis., (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.